Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...

The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a ...

The Food and Drug Administration approved Revuforj from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed or refractory acute ...

Syndax Pharmaceuticals (NASDAQ:SNDX) just reported positive results from the phase 2 portion of its AUGMENT-101m trial evaluating the use of Revumenib for the treatment of patients with relapsed ...

WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...

Also Read: FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication Among the patients who achieved CR/CRh, 12 had a CR, and three had a CRh.

On Wednesday, Goldman Sachs (NYSE:GS) updated its outlook on Syndax Pharmaceuticals (NASDAQ:SNDX), reducing the price target to $31 from the previous $33 while maintaining a Buy rating. The adjustment ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

On Wednesday, Goldman Sachs updated its outlook on Syndax Pharmaceuticals (NASDAQ:SNDX), reducing the price target to $31 from the previous $33 while maintaining a Buy rating. The adjustment ...

The competitive menin-inhibitor space chalked further data from Syndax Pharmaceuticals Inc., which disclosed positive top-line results from the pivotal phase II portion of the Augment-101 study, ...

While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is trying to build a case for its candidate in another. Though the drug met ...